Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06377267
Title Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial) (STROBE)
Acronym STROBE
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Vall d'Hebron Institute of Oncology
Indications
Therapies
Age Groups: senior | adult
Covered Countries ESP


No variant requirements are available.